Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, Q4 2010

Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, Q4 2010

Summary

Global Markets Direct’s, “Chronic Lymphocytic Leukemia Pipeline Review, Q4 2010”, provides an overview of the Chronic Lymphocytic Leukemia therapeutic pipeline. This report provides information on the therapeutic development for Chronic Lymphocytic Leukemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Chronic Lymphocytic Leukemia. “Chronic Lymphocytic Leukemia-Pipeline Review 2010, Q4 2010” is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- A snapshot of the global therapeutic scenario for Chronic Lymphocytic Leukemia.
- A review of the Chronic Lymphocytic Leukemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Chronic Lymphocytic Leukemia pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- A snapshot of the global therapeutic scenario for Chronic Lymphocytic Leukemia.
- A review of the Chronic Lymphocytic Leukemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Chronic Lymphocytic Leukemia pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products. SHOW LESS READ MORE >

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Chronic Lymphocytic Leukemia (CLL) Overview
Therapeutics Development
An Overview of Pipeline Products for Chronic Lymphocytic Leukemia (CLL)
Chronic Lymphocytic Leukemia (CLL) Therapeutics under Development by Companies
Chronic Lymphocytic Leukemia (CLL) Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Companies Involved in Chronic Lymphocytic Leukemia (CLL) Therapeutics Development
Bristol-Myers Squibb Company
Genzyme Corporation
Johnson & Johnson
F. Hoffmann-La Roche Ltd.
Abbott Laboratories
Biogen Idec Inc.
AstraZeneca PLC
Eli Lilly and Company
GlaxoSmithKline plc
Seattle Genetics, Inc.
Gilead Sciences, Inc.
Merck & Co., Inc.
Emergent BioSolutions Inc.
Lentigen Corporation
Novartis AG
Genta Incorporated
Nippon Shinyaku Co., Ltd.
PDL BioPharma, Inc.
Sunesis Pharmaceuticals, Inc.
Genmab A/S
Santaris Pharma A/S
Exelixis, Inc.
Astex Therapeutics Limited
Celgene Corporation
Bayer AG
Genitope Corporation
AEterna Zentaris Inc.
IMMUNOMEDICS, INC
InNexus Biotechnology Inc.
MethylGene Inc
Alexion Pharmaceuticals, Inc.
BioCryst Pharmaceuticals, Inc.
Portola Pharmaceuticals, Inc.
TopoTarget A/S
Pharmacyclics, Inc.
MorphoSys AG
DARA BioSciences, Inc.
Threshold Pharmaceuticals, Inc.
Synta Pharmaceuticals Corp.
Protox Therapeutics Inc.
SymBio Pharmaceuticals Limited
Arthur G. James Cancer Hospital & Richard J. Solove Research Institute
Kantonsspital Aarau AG
The University of Chicago
Memgen, LLC.
Italfarmaco S.p.A.
Calistoga Pharmaceuticals, Inc.
Curacyte AG
MAT Biopharma
Aegera Therapeutics Inc.
Ascenta Therapeutics, Inc.
Arno Therapeutics, Inc.
Fresenius Biotech GmbH
Semafore Pharmaceuticals, Inc.
Deciphera Pharmaceuticals, LLC
Polyphenon Pharma
Onconova Therapeutics, Inc
Gemin X Pharmaceuticals
SBI Biotech Co., Ltd.
KaloBios Pharmaceuticals, Inc.
Cylene Pharmaceuticals, Inc.
Nereus Pharmaceuticals, Inc.
Kyowa Hakko Kirin Pharma, Inc.
Mayo Clinic
Uppsala University Hospital
Laboratoire français de Fractionnement et de Biotechnologies
Advancell
Universities/Institutes Involved in Chronic Lymphocytic Leukemia (CLL) Therapeutics Development
Chronic Lymphocytic Leukemia (CLL) Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles – Companies
Arzerra - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Arzerra + Fludarabine + Cyclophosphamide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Flucam - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fludara - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fludarabine + Cyclophosphamide + Rituximab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Genasense - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Genasense + Fludarabine + Cyclophosphamide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ofatumumab + Chlorambucil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Revlimid - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RO5072759 + chlorambucil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SyB L-0501 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Late Stage Drug Profiles – Universities/Institutes
Alemtuzumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Alemtuzumab + Rituximab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
alemtuzumab + rituximab + cyclophosphamide + fludarabine phosphate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bendamustine + Rituximab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
chlorambucil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Chlorambucil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Chlorambucil_ - Drug Profile
Product Description
Mechanism of Action
R&D Progress
cyclophosphamide + fludarabine phosphate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cyclosporin + Methylprednisolone + Umbilical Cord Blood Stem Cell Transplantation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Darbepoetin alfa + Fludarabine phosphate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Filgrastim + Cyclophosphamide + Fludarabine Phosphate + Mitoxantrone Hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Filgrastim + Cyclophosphamide + Fludarabine Phosphate + Mitoxantrone Hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fludara + Cytoxan + Rituxan - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fludarabine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fludarabine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fludarabine + (Cyclophosphamide + Campath) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fludarabine + (Cyclophosphamide + Rituximab) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
fludarabine + cyclophosphamide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fludarabine + Cyclophosphamide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fludarabine + Cyclophosphamide + Rituximab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fludarabine + Total Body Irradiation + Allogeneic Hematopoietic Stem Cell Transplantation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
fludarabine phosphate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fludarabine phosphate + Cyclophosphamide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fludarabine Phosphate + Rituximab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fludarabine phosphate_ - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Nipent + Cytoxan + Rituxan - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Procrit - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Rituximab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rituximab + cyclophosphamide + fludarabine phosphate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Rituximab + Fludarabine + Cyclophosphamide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rituximab + fludarabine phosphate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Thiotepa + Cyclophosphamide + ATG + OKT3 + Rituximab + Radiation therapy + Stem cell tranplantation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Discontinued Products
Chronic Lymphocytic Leukemia (CLL) - Featured News
Dec 09, 2010: Memgen Presents Clinical And Preclinical Results Of Oncology Drug At ASH Annual Meeting
Dec 07, 2010: Pharmacyclics Reports Updated Clinical Results From Phase IA Trial Of PCI-32765
Dec 06, 2010: Aeterna Zentaris Presents Phase II Data Of Perifosine In Combination With Sorafenib In Advanced Leukemia And Lymphoma
Dec 06, 2010: Aeterna Zentaris Reports Preclinical And Interim Results Of Phase II Of Perifosine In Treatment Of Advanced Leukemia
Dec 06, 2010: Emergent Presents Positive Data From TRU-016 Program At American Society Of Hematology Meeting
Dec 05, 2010: Alexion Reports Positive Interim Results From Phase I/II Trial Of Samalizumab
Dec 05, 2010: Calistoga Reports Positive Results From CAL-101 Phase I Trial In Hematologic Malignancies
Dec 05, 2010: Calistoga Reports Positive Phase I interim Results From Combination Trial Of CAL-101 In Hematologic Malignancies
Dec 05, 2010: Pharmacyclics Reports Positive Results From Phase I Study Of PCI-32765 At ASH Annual Meeting
Dec 05, 2010: Pharmacyclics Reports Preclinical Data Of PCI-32765 In Chronic Lymphocytic Leukemia
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer